WORLD-FIRST EXPERIMENTAL CANCER TREATMENT PAVES WAY FOR CLINICAL TRIAL
Nature Medicine has published a peer reviewed paper detailing the experimental glioblastoma cancer treatment developed by Professor Georgina Long AO, Medical Director of Melanoma Institute Australia, paving the way for a clinical trial to be conducted by researchers at The Brain Cancer Centre in Melbourne.
Professor Long used her expertise in immunotherapy and drew on melanoma science to devise, lead and administer the treatment, the first documented use of neoadjuvant triple immunotherapy in glioblastoma.
LATEST NEWS
Addressing fear of cancer recurrence
A study has been released investigating the effectiveness of a Melanoma Care Program for patients with early-stage melanoma with varying degrees of fear of cancer recurrence after treatment of their primary melanoma.
Global accuracy of MIA risk tool predicting sentinel node metastasis
The extensive global use of MIA’s online tool for estimating the risk of nodal metastasis in newly diagnosed melanoma patients has prompted an international study to validate its accuracy & improve its precision across diverse populations worldwide.
Leading MIA researchers and clinicians share latest advances in Athens
MIA researchers and clinicians attended the World Congress of Melanoma, held in conjunction with the EADO Congress, in Athens.
Melanoma March 2025 in pictures
See all the photos from our Melanoma March 2025 events, and download yours.
Early career fellowship for Dr Rebecca Simpson
MIA researcher Dr Rebecca Simpson has been awarded a CINSW 2024 Early Career Fellowship which supports early & mid-career researchers through the development of research & leadership skills & innovative approaches to research.
Big thanks to our Community Fundraisers!
A big thank you to our wonderful community of fundraisers. Your dedication and the stories behind your fundraising efforts are inspiring. We are so grateful for your support to help us reach zero deaths from melanoma.
MIA’s MISSION
ZERO DEATHS FROM MELANOMA
MIA will achieve its mission through 3 pillars of action: Research, Clinical Care & Education.
MIA conducts its research under 4 themes: Prevention, Risk & Clinical Detection – Early Melanoma – Advanced Melanoma – Supportive Care & Survivorship.
1300
It is estimated 1300 Australians will die from melanoma this year
30 mins
1 Australian is diagnosed with melanoma every 30 minutes
90%
If caught early 90% of melanomas can be cured by surgery
Age 20-39
Melanoma is the most common cancer affecting Australians aged 20 to 39
